The Entirely Subcutaneous Defibrillator - A New Generation and Future Expectations

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• Conventional implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death (SCD) but are associated with significant complications.
• The development of an entirely subcutaneous ICD (S-ICD) marks a shift towards less-invasive defibrillation strategies.
• Patient selection is crucial, particularly for those at high risk of SCD who do not require pacing.

Purpose of the Study:

• To review the historical and current aspects of S-ICD technology.
• To evaluate the S-ICD as a therapeutic option for selected high-risk SCD patients.
• To discuss the safety and efficacy data emerging from clinical use and registries.

Main Methods:

• Review of existing literature and clinical data on S-ICD systems.
• Analysis of safety and efficacy outcomes from registries like EFFORTLESS.
• Examination of advancements in S-ICD technology, including newer device generations.

Main Results:

• The S-ICD has received CE Mark and FDA approval and is increasingly implanted globally.
• Clinical data, including the EFFORTLESS Registry, support the safety and efficacy of S-ICD.
• The latest S-ICD generation (EMBLEM) offers a smaller profile, extended longevity, and remote monitoring.

Conclusions:

• The S-ICD presents a viable, less-invasive alternative for SCD prevention in select patients.
• Ongoing technological innovations and potential integration with leadless pacing promise future advancements in defibrillation therapy.
• The S-ICD system is evolving to play a significant role in managing SCD risk.